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ABSTRACT
L-Nucleoside analogues such as lamivudine are
active for treating viral infections. Like D-nucleo-
sides, the biological activity of the L-enantiomers
requires their stepwise phosphorylation by cellular
or viral kinases to give the triphosphate. The
enantioselectivity of NMP kinases has not been
thoroughly studied, unlike that of deoxyribonucleo-
side kinases. We have therefore investigated
the capacity of L-enantiomers of some natural
(d)NMP to act as substrates for the recombinant
forms of human uridylate-cytidylate kinase,
thymidylate kinase and adenylate kinases 1 and 2.
Both cytosolic and mitochondrial adenylate
kinases were strictly enantioselective, as they
phosphorylated only D-(d)AMP. L-dTMP was a
substrate for thymidylate kinase, but with an
efficiency 150-fold less than D-dTMP. Both L-dUMP
and L-(d)CMP were phosphorylated by UMP-CMP
kinase although much less efficiently than their
natural counterparts. The stereopreference
was conserved with the 20-azido derivatives
of dUMP and dUMP while, unexpectedly, the
20-azido-D-dCMP was a 4-fold better substrate
for UMP-CMP kinase than was CMP. Docking
simulations showed that the small differences in
the binding of D-(d)NMP to their respective kinases
could account for the differences in interactions of
the L-isomers with the enzymes. This in vitro
information was then used to develop the in vivo
activation pathway for L-dT.
INTRODUCTION
Recent developments indicate that L-nucleosides and
L-nucleoside analogues are potent anti-viral, anti-tumour
and even anti-malarial agents (1–4). The L-derivative,
lamivudine (b-L-20,30-dideoxy-30-thiacytidine, 3TC), has
been approved for treating both HIV and HBV, while
emtricitabine (b-L-20,30-dideoxy-5-ﬂuoro-30-thiacytidine,
FTC) is used in HIV therapy. Telbivudine (b-L-thymidine,
L-dT) was recently approved for treating hepatitis B by the
US Food and Drug Administration. Many L-nucleosides
are currently in advanced clinical trials for the treatment
of a variety of virus diseases. These include clevudine [1-(2-
ﬂuoro-5-methyl-b-L-arabinofuranosyl)uracil, L-FMAU],
elvucitabine (20,30-didehydro-20,30-dideoxy-b-L-5-
ﬂuorocytidine, b-L-d4FC), valtorcitabine (val-b-L-20-
deoxycytidine, val-L-dC), pentacept (20,30-didehydro-20,
30-dideoxy-30-ﬂuoro-b-L-cytidine, b-L-30-Fd4C) and b-L-
20-Fd4C (20,30-didehydro-20,30-dideoxy-20-ﬂuoro-b-L-
cytidine). Most L-enantiomers considered for
treating virus diseases have similar activities to their
D-counterparts, but are less sensitive to degrading enzymes
and have better safety proﬁles (5,6). These properties are
due mainly to the enantioselectivity of the enzymes that
interact with these substrates in vivo (7). L-nucleosides
must be phosphorylated by cellular or viral kinases before
they can reach the targeted virus enzymes. The enantios-
electivity of the enzymes involved in nucleoside de novo
synthesis and salvage pathway is governed by no general
rule. Each individual metabolic enzyme must therefore be
studied. Among the four deoxyribonucleoside kinases in
human cells, cytosolic thymidine kinase 1 (TK1) is strictly
enantioselective while mitochondrial thymidine kinase
2 (TK2) is less speciﬁc (8–10). Deoxycytidine kinase
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enantioselective in vitro (9,11–12). The phosphorylation
of nucleoside monophosphates and their analogues
to their diphosphate derivatives is then carried out by
NMP kinases in both de novo and salvage pathways.
The NMP kinases in human cells include one dTMP
kinase, one UMP-CMP kinase, six isoenzymes of adeny-
late kinase and several guanylate kinases (13). Only the
abilities of hUMP-CMP and dTMP kinases to phosphor-
ylate some L-deoxynucleoside monophosphate analogues
has been studied to date (14–15). Finally, NDPK is strictly
enantioselective (16). The ﬁnal step can be carried out by
phosphoglycerate kinase, which has a broad substrate
speciﬁcity (17–18). Other ATP-synthesizing enzymes such
as creatine kinase can also be involved in this step (19).
Triphosphorylated L-derivatives can interact with viral
polymerases, acting as competitive inhibitors or alternate
substrates, usually leading to chain termination. Viral
polymerases incorporate L-derivatives more readily than
do the human ones (20–21). Nucleoside degrading
enzymes, such as nucleoside deaminases and phosphor-
ylases, tend to be strictly selective for D-nucleotides
although only limited data is available (11,22). The lack
of degradation of L-nucleosides has however been
demonstratedin mice, where L-nucleosides were gradually
excreted in the unchanged form following intraperitoneal
administration (5). 50-Nucleotidases also seem to be
moderately to highly enantioselective (7,23). The ribonu-
cleotide reductases, which catalyze the de novo conversion
of ribonucleotides to 20-deoxyribonucleotides, are also
key enzymes in DNA replication and repair. In vitro, these
enzymes are inhibited by 20-azido-20-deoxynucleoside
50-diphosphates (24–27). However, N3-D-dUrd is not
cytotoxic due to its poor intracellular phosphorylation.
The mechanism of enzyme inactivation and the enzymatic
monophosphorylation of the parent nucleosides has
been thoroughly studied (24–25). More recently, we have
shown that ribonucleotide reductase is enantiospeciﬁc
with respect to the natural conﬁguration of the sugar
moiety (26–27). This report examines the phosphorylation
of the b-D and b-L stereoisomers of 20-azido pyrimidine
monophosphates by human UCK, TMPK and AKs
and characterizes the enantioselectivity and the possible
cross-activities of these three human kinases for natural
(d)NMP (Figure 1).
Part of this work was presented during the XVIIth
Round Table for Nucleosides, Nucleotides and Nucleic
Acids in Bern, in September 2006.
MATERIALS AND METHODS
Natural D-nucleotides were purchased from Sigma chemi-
cals (St Louis, MO, USA). MABA-dTDP was synthesized
as described (28).
Synthesis of L-nucleoside 50-monophosphates
L-dA, L-dU, L-dC and L-dT were a generous gift from
Idenix Pharmaceuticals (http://www.idenix.com). L-ribo-
nucleosides were synthesized starting from L-ribose
following usual procedures. The azidonucleosides were
synthesized as previously described (26). L-Nucleoside
50-monophosphates (L-NMP) were prepared by selective
50-phosphorylation of the corresponding L-nucleosides
with POCl3 in triethylphosphate (29). L-NMPs were
puriﬁed on DEAE-Sephadex A-25 (elution: linear gradient
of TEAB pH 7.6 from 10 to 300mM) followed by RP18
chromatography (elution: water to methanol 50%).
The triethylammonium counter ions were exchanged for
sodium by passing the nucleotide solution through a
DOWEX-AG 50WX2-400 column. Yields were 43–80%.
The structures and purities of L-NMP were assessed
by nuclear magnetic resonance (
1H,
13C,
31P), fast-
atom-bombardment MS, UV spectroscopy, HPLC and
polarimetry. In some cases, it was necessary to separate
the nucleoside 50-monophosphate from traces of nucleo-
side 30-monophosphate. This was done by semi-prepara-
tive HPLC using Hypercarb, a porous graphite carbon
stationary phase (30).
The physico-chemical properties of the 20-azido-
20-deoxy D-nucleotides were identical, except for the ½  
20
D
value, to those of the corresponding 20-azido-20-deoxy
L-nucleotides.
N3-L-dUMP: ½  
20
D þ 29 (c 1.1, MeOH);
1H NMR (D2O,
300MHz) d 7.96 (d, 1H, J=8.1Hz, H–6), 5.93 (d, 1H,
J=5.3Hz, H–10), 5.87 (d, 1H, J=8.1Hz, H5), 4.48
(pt, 1H, J=5.1Hz, H30), 4.30 (pt, 1H, J=5.4Hz, H20),
4.16 (sl, 1H, H40), 4.04–3.90 (m, 2H, H50,H 5 00);
13C NMR
(D2O, 300MHz) d 166.2, 151.6, 141.6, 102.7, 86.9, 84.4,
70.3, 65.4, 63.2;
31P NMR (D2O, 300MHz) d+2.47;
UV (H2O)  max 260nm (" 9400); MS FAB+m/z 372
(M+H)
+, 350 (M–Na+2H)
+.N 3-D-dUMP: ½  
20
D   29
(c 1.1, MeOH). N3-L-dCMP: ½  
20
D   18 (c 1, H2O);
1H NMR (D2O, 300MHz) d 8.07 (d, 1H, J=7.6Hz,
H–6), 6.14 (d, 1H, J=7.6Hz, H5), 6.06 (d, 1H,
J=4.5Hz, H–10), 4.54 (pt, 1H, J=5.4Hz, H30), 4.34
(pt, 1H, J=5.1Hz, H20), 4.26–4.22 (m, 1H, H40),
4.16–4.04 (m, 2H, H50,H 5 00);
13C NMR (D2O, 300MHz)
d 166.1, 157.3, 141.3, 96.6, 87.7, 83.5, 69.8, 66.0, 62.9;
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L-dAMP β-L-2′-deoxyadenosine 5′-monophosphate adenine  H
L-dUMP β-L-2′-deoxyuridine 5′-monophosphate uracile  H
N3-L-dUMP β-L-2′-azido-2′-deoxyuridine 5′-monophosphate uracile  N3
L-CMP β-L-cytidine 5′-monophosphate cytosine  OH
L-dCMP β-L-2′-deoxycytidine 5′-monophosphate cytosine  H
N3-L-dCMP β-L-2′-azido-2′-deoxycytidine 5′-monophosphate cytosine N3
L-dTMP β-L-2′-deoxythymidine 5′-monophosphate  thymine H
Figure 1. Structures of b-L and b-D (deoxy)ribonucleoside monopho-
sphates (Base=adenine, thymine, uracil, cytosine).
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269nm (" 10500); MS FAB+m/z 371 (M+H)
+, 349
(M–Na+2H)
+.N 3-D-dCMP: ½  
20
D þ 18 (c 1.1, H2O).
Bacterial production and purification of His-tagged
NMP kinases
Human UCK, TMPK, AK1 and AK2 were produced in
Escherichia coli as recombinant proteins as previously
reported (15,31, Topalis, personal communication). E. coli
Rosetta (DE3)pLysS cells transformed with the appro-
priate expression plasmid were grown at 378Ci nL B
medium supplemented with 34mg ml
 1 chloramphenicol
and 50mg ml
 1 kanamycin. Gene expression was induced
by adding 0.5mM IPTG when the absorbance at 600nm
reached 0.8, and cells were grown at 308C for a further
3h. The cells were harvested, lysed by sonication and
centrifuged at 5000r.p.m., 88C, for 30min. The super-
natant was loaded onto a Ni-NTA column (Qiagen,
Germany) equilibrated with lysis buﬀer (50mM Tris-HCl,
300mM NaCl, 10mM imidazole, pH=8.0). The column
was washed with lysis buﬀer and the proteins eluted with
a linear gradient of imidazole, (0–250mM). The fractions
containing the enzyme were pooled and dialysed against
dialysis buﬀer (50mM Tris-HCl pH=7.4, 20mM NaCl,
1mM DTT, 50% glycerol). SDS-PAGE indicated that the
protein was over 95% pure.
Enzymatic assays
The activities of the NMP kinases were followed by a
coupled spectrophotometric assay (32). Assays were
carried out at 378C in the following reaction mixture
(total volume: 140ml): 50mM Tris-HCl, pH=7.4, 50mM
KCl, 5mM MgCl2, 1mM ATP, 0.2mM NADH, 1mM
phosphoenolpyruvate, 1mM DTT, 4U ml
 1 pyruvate
kinase, 4U ml
 1 lactate dehydrogenase. As the NDP
kinase from Dictyostelium discoideum is strictly enantio-
selective, this enzyme was only added (4U ml
 1) for assays
with a D-enantiomer substrate (32). The reaction was
started by adding the (d)NMP or (d)NMP analogue and
the decrease in absorbance at 340nm was measured.
The kinase concentrations were 4nM to 8mM in order
to measure initial rates below 0.2A/min. For inhibition
studies, the inhibitor was added after the enzyme, the
reaction was then started by adding the substrate(s).
The results were analysed using the KALEIDAGRAPH
software. Assays were carried out in duplicate or
triplicate.
Only 0.2mM ATP was added in the reaction mixture
for studies on the inhibition of hAK1 and hAK2.
Inhibition was studied at three inhibitor concentrations:
0, 400 and 600mM L-AMP for inhibiting the phosphor-
ylation of D-AMP by hAK1, and 0, 38 and 134mM L-AMP
for inhibiting the phosphorylation of D-dAMP by hAK2.
The inhibitor was added immediately after the enzyme,
and adding the substrate started the reaction. Data
were plotted on double reciprocal plots and the KI
values were determined by plotting the slopes against the
concentrations of inhibitor.
Fluorescence assays
The dissociation constants of hTMPK for both dTMP
enantiomers were measured using a ﬂuorescence assay
(28). Brieﬂy, the binding of the ﬂuorescent probe MABA-
dTDP to hTMPK in buﬀer T (50mM Tris-HCl, pH=7.5,
5mM MgCl2, 50mM KCl and 5% glycerol) resulted in
a 190% increase in ﬂuorescence intensity (excitation at
340nm and emission at 430nm with emission and
excitation slits at 2 and 4nm, respectively). The binding
constant was determined by titration of the ﬂuorophore
with the enzyme (KD=6mM). Competition titrations
with D-o rL-d(T/U)MP were done by mixing MABA-
dTDP (6mM) with the enzyme (6mM), so that, as
recommended, about half of the ﬂuorophore was
enzyme-bound at the start of the experiment (33). Upon
addition of increasing amounts of ligand, the ﬂuorescence
probe was gradually displaced from the enzyme active
site and the resulting decreases in ﬂuorescence were
monitored. The total speciﬁc signal was determined at
the end of each experiment by adding excess dTDP.
The data were corrected for dilution and plotted: IC50
values were obtained at half-displacement. The IC50
values are related to the dissociation constants for the
ligand, KD, and for the ﬂuorophore MABA-dTDP, KF
D,
by the following equation (33):
KD ¼ IC50KF
DB= AP þ BP  A þ B   KF
D
 
ð1Þ
where B is the initial concentration of bound MABA-
TDP, A is the total concentration of MABA-dTDP and
P is the total concentration of kinase (considered to be
monomers).
Modelling studies
L-nucleotides and nucleotides analogues were drawn on
Molsoft (http://www.molsoft.com, 2D to 3D converter)
and Smiles Translator (http://cactus.nci.nih.gov/services/
translate/) to produce the PDB ﬁles. The conformation of
the sugar ring was checked by visualizing the molecules
within the PyMOL graphic system and, if necessary,
modiﬁed to the b-L or b-D conﬁguration, as desired (34).
Docking of the L-nucleotides and nucleotide analogues
was performed using ArgusLab software (35). The binding
site was deﬁned from the coordinates of the ligand in
the original PDB ﬁles 2UKD for hUCK and 1E2D for
hTMPK. Docking precision was set to ‘high’ and the
‘ﬂexible ligand docking’ mode was used for each docking
run. Resulting complexes were visualized with the PyMOL
graphic system and the diagrams for each nucleotide
analogue/NMP kinase model obtained were drawn using
Chemdraw CambridgeSoft (ChemDraw, CambridgeSoft
Corporation, USA, http://www.camsoft.com).
RESULTS AND DISCUSSION
Strictstereospecificity of recombinant human AMP
kinases1and 2
The activities of the major adenylate kinases hAK1
(cytosolic) and hAK2 (in the inter-membrane space of
mitochondria) were measured in vitro as a function of the
Nucleic Acids Research, 2007, Vol. 35, No. 14 4897D- and L-(d)AMP concentrations as well as of pyrimidine
nucleoside monophosphates. Human AK1 and AK2 were
both speciﬁc for the D-enantiomers. They did not
phosphorylate L-(d)NMP, except for hAK2 having very
little action on L-dAMP corresponding to a ‘catalytic
eﬃciency’ about 10
4 smaller than for the D-stereoisomer
(Table 1). The rate of D-(d)AMP phosphorylation
increased with the substrate concentration, as expected
for Michaelis curves. The maximum rate Vmax of D-AMP
phosphorylation by hAK2 was not reached due to
substrate inhibition at concentrations above 0.3mM
(data not shown). This inhibition is generally attributed
to unproductive binding of the ligand at the same site or at
a secondary site. The reaction rates for hAK2 were slightly
below those for hAK1 but were almost compensated
for by the KM values, resulting in somewhat similar
catalytic eﬃciencies as might be expected from the
similarities of their active site sequences. D-dAMP was a
slightly poorer substrate than D-AMP for both hAK1 and
hAK2. The deoxyribonucleotides, D-dCMP and D-dUMP,
were not substrates for the AKs although these enzymes
phosphorylated the pyrimidine nucleotides, D-CMP and
D-UMP, to a minor extent (Table 1) (15).
L-AMP was bound by both enzymes. It competitively
inhibited the phosphorylation of D-AMP and D-dAMP by
hAK1 and hAK2, with an estimated KI of 200mM for
hAK1 and 18mM for hAK2 (data not shown). D-dAMP
was used because the mitochondrial AK2 was inhibited
by excess D-AMP. The binding of L-nucleotides to the
AMP site of hAK1 and hAK2 was thus unproductive.
Additionally, L-(d)AMP was also not a substrate for
hUCK or hTMPK (data not shown).
Despite this poor phosphorylation, L-dA reduced the
virus load in vivo in the woodchuck model of chronic
B hepatitis although less eﬃciently than L-dC or L-dT (6).
The other isoenzymes of AK, i.e. hAK3, 4, 5 and 6 could
contribute to the phosphorylation of L-(d)AMP and
explain this in vivo activity (36–37).
Relaxed stereospecificity ofrecombinant human
dTMP kinase
The recent approval of L-dT for treating hepatitis B has
prompted us to study the phosphorylation of L-dTMP
by hTMPK. The catalytic eﬃciency of the enzyme for
L-dTMP was around 0.7% that D-dTMP (Table 2). The
catalytic turnover number kcat was 10 times smaller than
that for D-dTMP, while the KM was 20-fold higher,
resulting in a lower kcat/KM (about 900M
 1s
 1)
(Figure 2A, Table 2). L-dTMP also gave rise to substrate
inhibition at 1mM and the KI value was estimated to be
5mM (Table 2). D-dUMP was a good substrate with an
eﬃciency in the 10
4M
 1s
 1 range, as already reported
(38), but the phosphorylation of L-dUMP very slow (kcat/
KM=60M
 1s
 1).
The relative binding constants for the L- and D-isomers
of dTMP were measured using the ﬂuorescent competition
assay based on the ﬂuorescent probe MABA-dTDP (28).
The dissociation constants for D-dTMP and L-dTMP from
hTMPK were 2mM and 45mM, respectively (Figure 2B).
The KD ratio was 22, comparable to the KM ratio, i.e.
19 (Table 2). Using the same assay, the nucleosides, D- and
L-dT, also competed with MABA-dTDP and had KD
values of 40 and 450mM, respectively, indicating that the
L-nucleoside also binds to the active site less eﬃciently
than its D-counterpart. The aﬃnity of the enzyme for
L-dTMP (KD=45mM), was greater than its aﬃnity for
D-dUMP (KD=150mM), which is a good substrate of the
enzyme (Figure 2B).
Activity ofrecombinant human UMP-CMP kinase with
D- and L-nucleoside monophosphates
L-dUMP and L-dCMP were substrates of hUCK, but they
were phosphorylated much more slowly than were
the natural nucleotides, despite the KM of the enzyme
being slightly more favourable for the L-compounds.
The KM values were 1.3mM for D-dUMP and 1.0mM
for D-dCMP, compared to 0.70mM for L-dUMP
and 0.73mM for L-dCMP (Figure 3, Table 3). But the
reaction rate was 20 times slower for L-dUMP than
for D-dUMP and 100 times slower for L-dCMP than for
Table 1. Catalytic parameters for the (d)AMP enantiomers with human
AMP kinases 1 and 2
Enzyme Substrate KM (mM) Relative
Vmax (%)
kcat/KM
(M
 1s
 1)
hAK1 D-AMP 0.14 0.02 100
a 3 10
6 (100
b)
D-dAMP 1.5 0.3 48 4 1.6 10
5 (5.3)
D-CMP 3.0 0.8 5.6 9.5 10
3 (0.32)
D-dCMP –
c –
c –
c
D-UMP 6 2 2.9 2.6 10
3 (0.08)
D-dUMP –
c –
c –
c
L-AMP –
c –
c –
c
L-dAMP –
c –
c –
c
hAK2 D-AMP
d 0.08 0.02 16 10
6 (33)
D-dAMP 0.21 0.05 22 5 10
5 (17)
D-CMP 6 11 3 1 0
4 (0.33)
D-dCMP –
c –
c –
c
D-UMP 9 2 0.32 180 (0.006)
D-dUMP –
c –
c –
c
L-AMP –
c –
c –
c
L-dAMP –
c –
c 70 (0.002)
aThe relative Vmax were obtained by comparing the kcat value of
the substrates to that of D-AMP. For Vmax standardization,
100 corresponds to 1240mmol of substrate transformed/min/mg,
i.e. to a kcat=500s
 1.
bThe relative eﬃciencies were obtained by comparing the kcat/KM
(M
 1s
 1) value of a substrate to that of D-AMP.
cNon detectable.
dhAK2 activity was inhibited by [AMP] 4 0.3mM, (KI=0.5mM).
Table 2. Catalytic parameters for the dTMP and dUMP enantiomers
with human TMP kinase
Substrate KM (mM) kcat (s
 1)k cat/KM (M
 1s
 1)K I (mM)
D-dTMP 0.020 0.005 3.0 0.1 1.5 10
5 (100
a)–
D-dUMP 0.17 0.01 4.8 0.6 2.8 10
4 (18) 2.6 0.9
L-dTMP 0.38 0.07 0.34 0.03 900 (0.7) 5 1
L-dUMP 2.3 0.2 0.13 0.01 60 (0.04) –
aRelative eﬃciency expressed by comparing the kcat/KM (M
 1s
 1) value
for a substrate to that of dTMP.
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Figure 2. Reaction of human dTMP kinase with the natural nucleoside
monophosphates dTMP and dUMP and their corresponding
L-enantiomers. (A) Saturation curves of dTMP kinase with (open
circle) D-dTMP, (ﬁlled circle) L-dTMP, (open triangle) D-dUMP and
(ﬁlled triangle) L-dUMP. The experiments were carried out in the
presence of 2mM ATP and 2mM Mg
2+ using the standard coupled
assay. The quantity of enzyme used in each experiment was: 0.18mM
for D-dTMP; 3mM for L-dTMP; 0.12mM for D-dUMP and 5mM
for L-dUMP. The KM and kcat values obtained by ﬁtting to a
hyperbole are shown in Table 1. The reaction rates v for D-dUMP
and L-dTMP as substrates [S] were best ﬁtted with Equation (2).
v ¼ V  ½ S  ðÞ = KM þ½ S þ ½S 
2=KI
 
(2) (B) Fluorescence competition
assays of diﬀerent substrates with MABA-dTDP bound to human
dTMP kinase. The ﬂuorescence of MABA-dTDP (6mM) was mon-
itored at 430nm (excitation wavelength at 340nm, excitation
slit=2nm, emission slit=4nm) in the presence of 6mM enzyme in
T buﬀer resulting in the binding of 40% of the ﬂuorophore.
The complex was titrated with (open circle) D-dTMP, (ﬁlled
circle) L-dTMP and (open triangle) D-dUMP. The IC50 values were
4.6, 82 and 260mM respectively. The dissociation constants KD
calculated according to Equation (1) were 2mM, 45mM and 0.15mM,
respectively.
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Figure 3. Reaction of human UMP-CMP kinase with the enantiomers of
(d)CMP and (d)UMP and their 20-azido-derivatives. (A) Saturation
curves of hUMP-CMP kinase as a function L-derivatives as substrates:
(ﬁlled circle) L-dCMP, (ﬁlled triangle) L-dUMP and (cross mark) L-CMP
obtained with respectively 0.4, 1 and 7.6mM of hUCK in the
reaction mixture. (B) Saturation curves of hUMP-CMP kinase with
the D-enantiomers of (open circle) dCMP and (inverted triangle)
N3-D-dCMP. The quantity of enzyme used was 4nM for dCMP and
0.8nM for N3-D-dCMP. The dash line represents the saturation curve
with D-CMP obtained with 4nM hUCK as shown in (15) and ﬁtted
to Equation (2). (C) Saturation curves of hUMP-CMP kinase
with the D-enantiomers of (open triangle) dUMP and (ﬁlled diamond)
N3-D-dUMP. The quantity of enzyme used was 4nM for dUMP and
N3-D-dUMP. The dash line represents the saturation curve with D-UMP
obtained with 4nM hUCK as shown in (15) and ﬁtted to Equation (2).
Nucleic Acids Research, 2007, Vol. 35, No. 14 4899its D-counterpart. L-CMP was also phosphorylated by
hUCK but it was a very poor substrate for this enzyme,
with a catalytic eﬃciency of 100M
 1s
 1, 10 times lower
than that for L-dCMP and 10
4 times lower than for D-
CMP. This decreased eﬃciency is due to a much lower
kcat, as the KM was similar to that for L-dCMP (0.75mM).
Excess of L-CMP was inhibitory, unlike the natural
substrate. The L-derivate that was the best substrate for
hUCK was L-dCMP, but it was far less eﬃcient than the
monophosphate form of the antiviral analogue L-3TC.
L-3TCMP is indeed phosphorylated to L-3TCDP by
hUCK with a catalytic eﬃciency kcat/KM of
2.8 10
5M
 1s
 1 (15).
Activity of recombinant human UMP-CMP kinase with
20-azido-20-deoxynucleotides
The activity of recombinant hUCK was evaluated using
the nucleoside analogues, N3-D-dCMP and N3-D-dUMP
(Figure 3). Both compounds were substrates of the
enzyme and followed Michaelis–Menten kinetics. High
concentrations did not give rise to substrate inhibition
of hUCK, unlike the natural substrates, D-CMP and
D-UMP. The KM values were 0.36mM for N3-D-dCMP
and 0.9mM for N3-D-dUMP compared to 20mM for
D-CMP and 50mM for D-UMP (Table 3). Despite the
higher KM values, the catalytic eﬃciencies for phosphor-
ylation of the 20-azido derivatives were in the same order
of magnitude (10
5–10
6) as those for the natural substrates
of the enzyme. The reaction rate with N3-D-dUMP was
similar to that with D-UMP (Figure 3, Table 3). The
reaction rate of hUCK with N3-D-dCMP was almost
4 times faster than that with D-CMP, demonstrating that
N3-D-dCMP is currently the best-known substrate for
hUCK (Figure 3B). Other enzymes hAK1, hAK2 and
hTMPK did not signiﬁcantly phosphorylate these
substrates.
The enantioselectivity of hUCK for 20-azido-20-deoxy-
nucleoside monophosphates was also evaluated.
The KM value for N3-L-dCMP was increased (1.2mM)
while the Vmax was lower (1.1U mg
 1), leading to a 4000-
fold lower catalytic eﬃciency than for the D-enantiomer
(Table 3). N3-L-dUMP was also a poor substrate of the
enzyme, with a KM of 1.3mM and a kcat of
0.34s
 1(Table 3). The 20-azido group was thus only
favourable for the D-analogues. Overall, in the L-series,
the pyrimidine 20-deoxyribonucleotides were better sub-
strates than the pyrimidine ribonucleotides and the
20-azido-20-deoxyribonucleotides, indicating that 20-
substitutions may cause steric hindrance for L-NMP
binding to hUCK.
Structural analysis of theenantioselectivity of human AMP,
TMP andUMP-CMP kinases
The NMP kinases all have a highly conserved structure
with a central CORE domain that contains an ATP
binding loop (P-loop) and two mobile domains: an NMP
binding domain and an LID domain, which provide the
catalytic residues for the reaction (39). Both the NMP and
LID domains are extremely mobile and undergo large
‘hinge bending’ motions (40). The same conformational
changes are believed to occur in all NMP kinases when
they switch from their opened to closed conformation
upon substrate binding. The X-ray structure of hAK1
complexed with the bisubstrate inhibitor Ap5A was
recently solved: it showed the interactions of AMP with
the active site in the closed conformation (41). The
structure of hTMPK complexed with various ligands
has been thoroughly explored (42), but the structure of the
free apoenzyme is not known. In contrast, the structure
of hUCK is only known in its open conformation (43).
Substrate-free hTMPK probably also exists in an opened
conformation and substrate-bound hUCK probably
adopts a closed conformation as does the homologous
enzyme from Dictyostelium (44).
L-AMP and L-dTMP were tentatively docked in the
closed conformation of hAK1 and hTMPK, and L-dCMP
was docked in an enzyme model based on
the Dictyostelium UCK (44). The docking of L-(d)AMP
in hAK1 failed to provide a model (data not shown): this
could be due to the rather speciﬁc interactions of D-AMP
with the protein, which are not mediated by water
molecules, thus limiting its capacity to accommodate
other substrates. The docking of L-deoxypyrimidine
monophosphates in hTMPK and UCK was more
successful (Figures 4 and 5). The dTMP and CMP binding
sites are represented as four interacting motifs: (i) the LID
domain, (ii) the P-loop, (iii) the mobile part of NMP
binding domain and (iv) the stable part of NMP binding
domain. The binding of L-dTMP diﬀered from that of
D-dTMP, especially at the deoxyribose moiety (Figure 4).
The H-bonds between the ﬁrst layer residues and the
thymine ring involved several water molecules, providing
a ‘ﬂexible’ NMP binding domain that readily accommo-
dates modiﬁed substrates. The thymine ring was stacked
onto Phe72 in L-dTMP binding, but it was not optimal,
as the base was shifted through 158. The interaction of
the phosphate group with Mg
2+ion and Asp15 in the
P-loop, via a water molecule, was conserved, as was its
interaction with Arg97 from the mobile NMP domain.
Table 3. Catalytic parameters for the (d)CMP, (d)UMP enantiomers
and their 20azido analogues with human UMP-CMP kinase
Substrate KM (mM) Relative Vmax (%) kcat/KM (M
 1s
 1)
D-CMP 0.020 0.005 100
a 6.5 10
6 (100
c)
D-dCMP 1.0 0.1 61 47  10
4 (1.2)
L-CMP 0.75 0.07 0.054 0.001 100 (0.0015)
L-dCMP 0.73 0.06 0.63 0.02 1000 (0.015)
N3-D-dCMP 0.36 0.03 408 9 1.5 10
6 (23)
N3-L-dCMP 1.2 0.1 0.36 0.02 390 (0.006)
D-UMP 0.05 0.01 100 2.8 10
6 (43)
D-dUMP 1.3 0.3 5.1 0.5 6000 (0.1)
L-dUMP 0.70 0.09 0.28 0.02 530 (0.008)
N3-D-dUMP 0.9 0.2 89 6 1.4 10
5 (2.15)
N3-L-dUMP 1.3 0.1 0.07 0.02 270 (0.004)
L-3TCMP
b 0.15 0.02 27 2.8 10
5 (4.3)
aThe relative Vmax was obtained by comparing the kcat value of the
substrates to that of D-CMP. Vmax=100 corresponds to 350mmol of
substrate transformed/min/mg, i.e. to a kcat=130s
 1 [from (15)].
bdata from (15) for comparison.
cThe relative eﬃciencies were obtained by comparing the kcat/KM
(M
 1s
 1) value of the substrates to that of D-CMP.
4900 Nucleic Acids Research, 2007, Vol. 35, No. 14However, the deoxyribose 30OH, which interacts with the
LID Gln157 via a water molecule in the D-dTMP/hTMPK
complex, was modelled as being H-bonded to the NH2 of
the highly conserved Arg45 of the immobile NMP domain
in the L-dTMP/hTMPK model.
The major interactions responsible for the binding of
D-CMP to hUCK involved the base and phosphate
(Figure 5). The interaction of Asn100 with the 4-amino
group of the cytidine base played an important role in the
base speciﬁcity and explains why D-(d)CMP is a better
substrate than D-(d)UMP (43). The phosphate does not
interact with the P loop as in hTMPK but strongly
connects the LID domain (Arg134 and Arg140) to the
immobile NMP domain (Arg39, Arg96 and Glu36)
(Figure 5A). These residues still interacted with L-dCMP
phosphate group in the L-dCMP/UCK model, except for
Arg134 (Figure 5B). The cytidine moiety for both D-CMP
and L-dCMP was H-bonded to Val63 and Asn100 from
the mobile NMP domain, resulting in similar positioning
of the base for both enantiomers. The L-nucleotide did not
have the major interaction of the D-CMP 20OH with the
main chain Lys61 carbonyl, contained within the NMP
mobile domain. L-dCMP was a better substrate for hUCK
A
B
Figure 4. Scheme of the acceptor-binding site of human dTMP kinase
in the closed form: (A) with D-dTMP bound to the acceptor-binding
site; (B) with L-dTMP modelled in the acceptor-binding site. LID (red),
P-loop (pink), immobile NMP domain (black) and mobile NMP
domain (blue).
A
B
C
Figure 5. Scheme of the acceptor-binding site of human UMP-CMP
kinase in the closed form. (A) with D-CMP bound to the acceptor-
binding site. (B) with L-dCMP modelled in acceptor-binding site. (C)
N3-D-dCMP bound to acceptor-binding site.
Nucleic Acids Research, 2007, Vol. 35, No. 14 4901than was L-CMP, probably due to 20-OH steric hindrance.
However, the ring oxygen in L-dCMP interacted with
Arg96, anchoring the sugar to the immobile NMP domain
(Figure 5B).
The model obtained with N3-D-dCMP bound to hUCK
had favourable interactions as the azido group interacts
with both Asp142 in the LID domain and the a-carbonyl
of Gly60 in the mobile NMP domain (Figure 5C). The
20OH of the ribonucleotide has been shown to contribute
to the LID closure of hUCK by its interaction with the
carbonyl of Lys61 located in the mobile NMP domain
(43). This interaction also explains the higher aﬃnity
of the enzyme for D-ribonucleotides compared to
D-deoxyribonucleotides. The replacement of 20-hydroxyl
by a bulkier azido group prevents complete closure of
the LID, which results in higher KM values. However,
the opening of the LID, which promotes product release,
is proposed to be the rate-limiting step of the reaction
catalyzed by hUCK. A recent NMR experiment on
hyperthermophilic and mesophilic homologues of AK
also suggested that the opening of the AMP binding and/
or LID domains upon product release was the rate-
limiting step inﬂuencing the catalytic turnover (45,46).
The azido group might thus facilitate the LID opening
or could connect the LID and mobile-NMP domains and
synchronize their opening, explaining the higher rate of
phosphorylation of N3-D-dCMP compared to D-CMP.
Dynamic studies should help to understand these higher
rates.
CONCLUSION
We have compared the activities of the kinases on L- and
D-nucleotides and shown that both hTMPK and hUCK
have relaxed enantioselectivities for dNMP, while hAK 1
and 2 are strictly devoted to D-(d)NMP. The pyrimidine
kinases phosphorylated only L-derivatives of the deoxy
series. UCK was active with L-dCMP but far less
eﬃciently than with L-3TCMP (15). hTMPK, hUCK,
hAK1 and hAK2 all phosphorylated their respective
D-(d)NMP with some minor cross-reactivity. For example,
D-CMP was phosphorylated eﬃciently by hUCK (kcat/
KM=6.5 10
6M
 1s
 1) and more slowly by hAK1 and
hAK2 (kcat/KM about 10
4M
 1s
 1). D-dUMP was a better
substrate for hTMPK (kcat/KM=2.8 10
4M
 1s
 1) than
for hUCK (kcat/KM=6 10
3M
 1s
 1). N3-D-dCMP was
the best D-series substrate for hUCK with a kcat 4-fold
higher than that for the natural substrate (D-CMP). This
could be due to a tighter interaction between the
LID domain and the NMP domain as explained by the
structural analysis.
RNAi studies have shown that hTMPK is implicated in
the activation of L-FMAU (47). There was generally a
good correlation between kinetic studies and the antiviral
eﬀect, emphasizing the need for eﬃcient cellular activation
of the antiviral drug to its triphosphate form, as shown for
L-3TC (15). The present study demonstrates the activity
of hTMPK on L-dTMP, even if the catalytic eﬃciency
was relatively low (kcat/KM=900M
 1s
 1). L-dTMP had
the highest relative phosphorylation eﬃciency of all the
L-(d)NMP tested. The phosphorylation of L-dTMP
correlates with studies on the intracellular metabolism of
L-dT in HepG2 cells and primary cultures of human
hepatocytes. The conversion of L-dTMP to L-dTDP
clearly appears to be the rate-limiting step in both cell
types (48). The ﬁrst phosphorylation of L-dT is believed to
be carried out by either hdCK or hTK2 with catalytic
eﬃciencies of 1.6 10
4M
 1s
 1 and 1 10
7M
 1s
 1,
respectively (9). The recent crystallization of dCK with
L-3TC and troxacitabine shows how the nucleoside
binding site of dCK can conserve all essential interactions
with these analogues or L-dC and thus maintain produc-
tive substrate positioning for phosphoryl-transfer (49).
Given the great similarity between dCK and hTK2, we can
assume that they are similarly ﬂexible for the productive
positioning of L-dT, explaining the high catalytic eﬃ-
ciency. The binding of L-dTMP to hTMPK is not optimal
and may be the rate-limiting step in the pathway.
NDPK does not recognize L-(d)NDP as substrates and
phosphoglycerate kinase is probably involved in the
conversion of L-dTDP into L-dTTP, with a catalytic
eﬃciency of 500M
 1s
 1 (18). From these in vitro data,
the second and third phosphorylation steps have low
catalytic eﬃciencies and appear rate-limiting in the
activation pathway. This study demonstrated the relaxed
enantioselectivity of hTMPK, which is most likely
essential to the formation of L-dTTP in vivo and thus to
the antiviral properties of L-dT.
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